![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
DNA-based vaccination is a promising approach to cancer immunotherapy. DNA-based vaccines specific for tumor-associated antigens (TAAs) are indeed relatively simple to produce, cost-efficient and well tolerated. However, the clinical efficacy of DNA-based vaccines for cancer therapy is considerably limited by central and peripheral tolerance. During the past decade, considerable efforts have been devoted to the development and characterization of novel DNA-based vaccines that would circumvent this obstacle. In this setting, particular attention has been dedicated to the route of administration, expression of modified TAAs, co-expression of immunostimulatory molecules, and co-delivery of immune checkpoint blockers. Here, we review preclinical and clinical progress on DNA-based vaccines for cancer therapy.
Acknowledgments
GK is supported by Ligue contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). LG is supported by WCMC (intramural funds) and Sotio a.c. (Prague, Czech Republic).
Abbreviations
| AE | = | adverse event |
| APC | = | antigen-presenting cell |
| AML | = | acute myeloid leukemia |
| CAF | = | cancer-associated fibroblast |
| CDR | = | complementarity-determining region |
| CEA | = | carcinoembryonic antigen |
| CIN | = | cervical intraepithelial neoplasia |
| CML | = | chronic myeloid leukemia |
| CT | = | cancer-testis |
| CTL | = | cytotoxic T lymphocyte |
| DC | = | dendritic cell |
| DOM | = | domain of tetanus toxoid |
| ER | = | endoplasmic reticulum |
| HNSCC | = | head and neck squamous cell carcinoma |
| HPV | = | human papillomavirus |
| ICB | = | immune checkpoint blocker |
| IL | = | interleukin |
| NSCLC | = | non-small cell lung carcinoma |
| OS | = | overall survival |
| PADRE | = | pan-DR epitope |
| PFS | = | progression-free survival |
| TAA | = | tumor-associated antigen |
| TCR | = | T cell receptor |
| TLR | = | Toll-like receptor |
| TNBC | = | triple-negative breast cancer |
| TSA | = | tumor-specific antigen |